drugset / Trial / NCT06753565

L-carnitine Supplementation in Rheumatoid Arthritis Patients

NCT06753565 ↗

Phase 2 Recruiting 60 enrolled German University in Cairo
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.

Timeline

Start
2024-12-31
Primary completion
2025-06
Completion
2025-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject L-carnitine Other / unclassified 500 mg —
Background Hydroxychloroquine Small molecule — —
Background Leflunomide Small molecule — —
Background Methotrexate Small molecule — —
Background Sulfasalazine Small molecule — —

Indications